{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.6","upperLimit":"11.9","value":"3.0"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"9.8","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo observation until disease progression.","id":"OG000","title":"Arm A (Observation)"},{"description":"Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.","id":"OG001","title":"Arm B (Pemetrexed)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline up to 3 years","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}